Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Increases By 143.8%

Hoth Therapeutics, Inc. (NASDAQ:HOTH) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 783,318 shares, a growth of 143.8% from the January 15th total of 321,350 shares. Based on an average daily volume of 903,297 shares, the short-interest ratio is currently 0.9 days. Approximately 5.4% of the shares of the company are sold short. Approximately 5.4% of the shares of the company are sold short. Based on an average daily volume of 903,297 shares, the short-interest ratio is currently 0.9 days.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Wall Street Zen lowered shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. Finally, D. Boral Capital restated a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a research report on Thursday, December 4th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Hoth Therapeutics has a consensus rating of “Hold” and a consensus price target of $5.00.

Institutional Trading of Hoth Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Lido Advisors LLC purchased a new stake in shares of Hoth Therapeutics in the third quarter worth about $32,000. Kestra Private Wealth Services LLC purchased a new position in Hoth Therapeutics in the 3rd quarter worth approximately $51,000. Geode Capital Management LLC grew its position in Hoth Therapeutics by 8.0% in the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after acquiring an additional 9,071 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Hoth Therapeutics during the third quarter worth $184,000. Finally, Citadel Advisors LLC purchased a new position in shares of Hoth Therapeutics in the third quarter valued at $232,000. 7.08% of the stock is currently owned by institutional investors and hedge funds.

Hoth Therapeutics Trading Up 4.1%

NASDAQ:HOTH traded up $0.04 on Friday, hitting $1.02. 711,163 shares of the stock were exchanged, compared to its average volume of 706,548. The stock has a fifty day moving average of $1.03 and a 200-day moving average of $1.26. The stock has a market cap of $15.82 million, a PE ratio of -0.96 and a beta of 0.56. Hoth Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $2.12.

Hoth Therapeutics (NASDAQ:HOTH) last posted its earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.20). As a group, analysts predict that Hoth Therapeutics will post -1.36 earnings per share for the current year.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.